Evidence map›Paper›PMID 40487425›Full record

ArticleiScience2025

A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability.

Maurice A G M Kroon, Hanneke W M van Laarhoven, Eleonora L Swart, Olaf van Tellingen, E Marleen Kemper

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Plants (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maurice A G M KroonDepartment of Pharmacy and Clinical Pharmacology, Amsterdam University Medical Center, AMC, 1105AZ Amsterdam, the Netherlands.
Hanneke W M van LaarhovenDepartment of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, 1081HV Amsterdam, the Netherlands.
Eleonora L SwartDepartment of Pharmacy and Clinical Pharmacology, Amsterdam University Medical Center, AMC, 1105AZ Amsterdam, the Netherlands.
Olaf van TellingenDivision of Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066CX Amsterdam, the Netherlands.
E Marleen KemperDepartment of Pharmacy and Clinical Pharmacology, Amsterdam University Medical Center, AMC, 1105AZ Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This independent crossover study assessed curcumin bioavailability and excretion in nine healthy males receiving three formulations (AOV, Longvida, and NovaSOL) at about 570 mg, while AOV was also tested at 2280 mg, with and without piperine. Plasma levels of unconjugated curcumin remained below 2 nM in most cases, including high-dose AOV and piperine combinations. NovaSOL achieved the highest levels (6.7-38 nM at 30 min), but these rapidly declined and were still 100-fold lower than concentrations used

Indexed as

Cell biologyPharmaceutical science

Identifiers

PMID40487425
PMCPMC12144411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.